Skip to content
10-K

Annual Report

ALSERES PHARMACEUTICALS INC /DE

0001193125-13-136073

← back to feed
Filed
Apr 1, 2013 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2012 · Mar 15, 2013 30.64M sh
Stock Repurchased FY 2012 · Dec 31, 2012 $28.22K
Stock Repurchased FY 2012 · Dec 31, 2011 $18.26K
Capex FY 2012 · Dec 31, 2012 $1.65M
Capex FY 2012 · Dec 31, 2011 $2.37K
Operating Cash Flow FY 2012 · Dec 31, 2012 −$160.55M
Operating Cash Flow FY 2012 · Dec 31, 2011 −$2.48M
Sga Expense FY 2012 · Dec 31, 2012 $70.41M
Sga Expense FY 2012 · Dec 31, 2011 $2.03M
Net Income FY 2012 · Dec 31, 2012 −$198.69M
Net Income FY 2012 · Dec 31, 2006 −$143.5M
Operating Income FY 2012 · Dec 31, 2012 −$196.75M
Operating Income FY 2012 · Dec 31, 2011 −$1.57M
Revenue FY 2012 · Dec 31, 2012 $1.43M
Stockholders Equity FY 2012 · Dec 30, 2012 −$26.72M
Short Term Investments FY 2012 · Dec 31, 2011 $27.45K
Current Liabilities FY 2012 · Dec 31, 2011 $30.42M
Total Liabilities FY 2012 · Dec 31, 2011 $30.42M
Current Assets FY 2012 · Dec 31, 2011 $168.25K
Total Assets FY 2012 · Dec 31, 2011 $170.73K
Cash And Equivalents FY 2012 · Dec 31, 2010 $98.51K